Francesco De Santis and Italfarmaco

Francesco De Santis enters in Italfarmaco in 1981 at the age of 25 and has been covering during his career the different positions of Managing Director, Director of the Board, President of Italfarmaco Spa and is President of Italfarmaco Holding. He has personally driven the foundation and internationalization process of all of the Group’s companies.

"A number of success factors, that are inherent to Italfarmaco’s identity, have allowed the company to maintain its growth in the past 10 years. First of all, it is a family company... able to establish long-term plans without being affected by the market’s ups and downs. In addition, Italfarmaco always remained committed to research and innovation..."
Francesco De Santis, Focus Reports, April 2009

"...Whereas Italfarmaco’s main driver is research, the second one is surely international expansion. A consistent share of the revenues generated is reinvested to fulfil global ambitions and conquer new markets..."
Francesco De Santis, Focus Reports, July 2009

Statements & Interviews »

Research in pharmaceutical field

Francesco De Santis elected vice-president with responsibility for Research and Development
The General Council of Confindustria, upon proposal of the designated President Carlo Bonomi, approved the presidency team for the 2020-2024 period.
Il Sole 24 Ore, 30 April 2020
la Repubblica, 30 April 2020

Newly appointed nominations in Farmindustria: FDS relected Vice President
In order to nominate the new executive board for the two year period 2015-2017, Farmindustria’s associative meeting held in Rome on July the 2rd 2015 has relected Francesco De Santis Vice President and member of the chairmanship's committee (in all, five Vice Presidents take part in the committee).
Pharmakronos, 2 July 2015

New laboratories C4T, Tor Vergata Centre – Pharmaceutical Industry
The new research centre called C4T (Colosseum Combination Chemistry Centre for Technology) is the result of the joint venture between Italian pharmaceutical industries (among which Italfarmaco) and the University of Tor Vergata. C4T develops projects carried out in partnership with academic groups of excellence both on national and international levels and offers research services for some of the most important pharmaceutical firms active in Italy...
Pharmakronos, 18 May 2011

Press Reviews »

"... great attention to women’s health: a mission shared by pharmaceutical companies.
To promote social awareness on the risk factors linked to women’s health (not only on reproductive aspects but also on social roles). To support a female health wise culture and encourage awareness concerning principles of equity and equal opportunity. To stimulate research on the major pathologies concerning women’s universe and their social, political and economical consequences (to increase the value of scientific knowledge and spread appropriate information)..."
Francesco De Santis, Delegate of Farmindustria for Research
L'industria farmaceutica e l'equità di genere, Quaderni della SIF, 2009, vol.17.

Publications »


President of Italfarmaco Holding S.p.A.

Vice Presidente of Confindustria with responsibility for Research and Development for the four-year period 2020-2024.

Vice President of Farmindustria since 2013, and previously also for the two-year period 1999-2001.

Vice Chairman of the Control Committee of the Code of Ethics of Farmindustria since 2003.

Chairman of the Control Committee for the Code of Ethics from 2002 to 2003.

Representative of Farmindustria at the General Council of Confindustria for the two-year period 2017-2019.

Member of the Confindustria Research & Development Technical Group in 2017.

Member of the Confindustria Research and Innovation Technology Committee from 2012 to 2014.

Delegate for Farmindustria Research and CRUI Relationships

1989-2005 Member of the Board of Directors of SISF - Società Italiana Scienze Farmaceutiche

1984-1985 Member of The New York Academy of Science

Curriculum »


Italfarmaco, one of the leading Italian pharmaceutical groups, operates in both the pharmaceutical and the fine chemical industries.
The company was founded in Milan in 1938.
The Italfarmaco Group now markets ethical products in Italy, Switzerland, Spain, Portugal, Greece, Russia, Turkey, Chile, Peru, Morocco and also for the subsidiary Chemi SPA in USA and Brazil. Total employees is over 3000 and total turnover exceeds 700 million euros.
Its products, all of which have a high therapeutic content, are mainly used in the cardiovascular, immuno-oncological, gynaecological, dermatological, orthopaedic and neurological areas.
The group owns modern, sophisticated industrial plants at which it manufactures its proprietary drugs to the highest quality standards. The first plant, at which injectables and solid oral drugs are manufactured, is situated in Milan, and a second manufacturing unit, for the production of liquid oral drugs, is located in Madrid.